Should you buy Neil Woodford’s top 3 holdings Imperial Brands plc, AstraZeneca plc & GlaxoSmithKline plc?

Edward Sheldon looks at the top three holdings of one of the UK’s best known fund managers, Neil Woodford: Imperial Brands plc (LON: IMB), AstraZeneca plc (LON: AZN) and GlaxoSmithKline plc (LON: GSK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford is among the most well-known fund managers in the UK. Given his star status, many private investors monitor Woodford’s key holdings in an attempt to clone his investment strategy.

So let’s look at the top three holdings in the Woodford Equity Income Fund and examine if they’re worth buying.

Financial market volatility

But first, let’s remember that there could be a great deal of near-term volatility in the financial markets after Friday’s EU referendum Brexit vote. The unexpected result has caused unprecedented amounts of uncertainty and if there’s one thing financial markets don’t like, it’s uncertainty.

Having said that, Woodford has made his stance clear on the result and has said he believes Britain’s long-term economic future will be largely unaffected by the decision to leave the EU. He’s also stated that his portfolio strategy will not change.

So with that in mind, here are Neil Woodford’s largest holdings.

Tobacco King

Woodford’s largest holding (7.6% of the fund) is tobacco giant Imperial Brands (LSE: IMB).

Tobacco stocks don’t suit everyone’s investing tastes, but Woodford has made it clear that he remains a strong fan of both Imperial Brands and rival British American Tobacco.

There’s no doubt Imperial Brands has performed well for his portfolio. The stock has delivered total annualised returns of almost 18% per annum over the last five years. But is this a reason to buy Woodford’s largest holding?

For me, the key question with Imperial Brands comes down to the long-term sustainability of tobacco revenues. I generally look for long-term revenue drivers when searching for investment opportunities, and personally I’m not 100% convinced about the sustainability of the tobacco industry over time.

Having said that, I can see plenty of reasons why investors could be interested in buying Imperial Brands right now though. The stock trades on a respectable P/E ratio of 15.5 times next year’s earnings, yields an excellent dividend of just under 4%, has high levels of free cash flow and could be seen as a ‘defensive’ stock in times of uncertainty.

Another key benefit of Imperial Brands is that it generates revenues from all over the world, so a weaker pound would be good for earnings. If you’re interested in a safety stock for the current volatile environment, Imperial Brands could be worth a look.

Healthcare theme

Woodford’s next two largest holdings are healthcare giants AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK) at 7.2% and 6.4% of the portfolio, respectively.

Healthcare is a theme that I like and with the global population ageing, I believe it’s a theme that could drive long-term revenues going forward. It’s also one that could provide some insulation from Brexit-related market volatility as healthcare is also considered to be a defensive sector.

While both companies have struggled for revenue growth over the last few years, a key attraction of these stocks is their sizeable dividend payouts. AstraZeneca yields around 5.1% while GlaxoSmithKline pays out an even bigger 5.4%.

One concern is that last year both companies’ dividends exceeded their earnings from continuing operations, which isn’t ideal. It’s an issue to keep an eye on going forward in the current volatile market. However, I can see the attraction of buckling down with these two healthcare powerhouses.

Edward Sheldon owns shares in GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Front view of aircraft in flight.
Investing Articles

Is it game over for the BP share price rally?

The BP share price has looked like a one-way bet in recent weeks as oil and gas prices soar but…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Amid geopolitical and AI risks, here’s how I’m positioning my ISA and SIPP in 2026

Edward Sheldon explains how he's allocating capital within his investment accounts and SIPP amid the various risks to the market.

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

My game plan for the next stock market crash

Markets have been surprisingly resilient during the recent Middle East conflict but we still cannot rule out a stock market…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

1 top growth stock to consider buying after it crashed 59%

This S&P 500 growth stock has fallen off a cliff lately due to AI software fears. Our writer thinks this…

Read more »

A mature woman help a senior woman out of a car as she takes her to the shops.
Investing Articles

Here’s how a 35-year-old putting £15 a day into an ISA could end up earning £18k+ of passive income annually!

A 35-year-old with no ISA but a willingness to invest relatively small sums could one day be earning many thousands…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

With the potential to double in 10 years, this could be a dividend stock to consider buying

With a yield of 7.2%, income investors might consider buying this stock. But reinvesting the dividends could deliver even more…

Read more »

Happy couple showing relief at news
Investing Articles

How much would someone need to invest in the stock market to target a £1,250 monthly second income?

Investing in the stock market can help deliver long-term wealth. But James Beard says it can also be a way…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How much would someone need in an ISA to aim to treble the current State Pension?

Experts say the State Pension isn’t generous enough to provide a comfortable retirement. James Beard says the stock market could…

Read more »